“Life science research and development is vital to creating the treatments that help people heal, survive and live longer,” Governor Hochul said. “Through our targeted efforts, we are working to ensure that cutting edge companies like French One Biosciences not only grow here, but that the next generation of medical breakthroughs happen in New York State.”
French One Biosciences has chosen Albany as its first U.S. location, planning to staff and equip a high-complexity laboratory and computational analytics operation, capable of advancing next-generation cancer diagnostics and therapeutic decision-support.
One Biosciences SAS, based in Paris, will bring its proprietary technology to this first-of-its-kind hub in Albany to address the unmet clinical and scientific needs to characterize the tumour ecosystem. The company is developing technology to better understand each patient’s cancer, helping doctors around the world to match patients to the therapies most likely to help them.
Empire State Development (ESD) is supporting this site location with up to $525,000 in performance-based Excelsior Jobs Program tax credits in exchange for the company’s job commitments, which anticipate 42 life science jobs and $18 million in investments over the next five years.
One Biosciences Executive Chairman Dr. Vincent Miller said, “We are excited to accelerate support of our pharma, biotech, and academic collaborators through our AI-driven single-cell technologies, which will ultimately benefit physicians and their patients. The local Albany life sciences ecosystem gives us access to a community of like-minded researchers and physicians committed to leveraging technology to improve health and is an ideal location from where to serve the US globally. We are grateful for Governor Hochul’s support.”
Citing Dr. Dorcey Applyrs, the City of Albany Mayor “This is a strong vote of confidence in Albany and in the growing life sciences ecosystem across the Capital Region. Welcoming One Biosciences to our city brings new, high-quality jobs and positions Albany at the forefront of cutting-edge research that has the potential to improve lives around the world. With our proximity to leading academic and healthcare institutions, and a workforce ready to meet the demands of this industry, Albany is well positioned to support companies that are advancing innovation in health and science. I am grateful to Governor Hochul and our state partners for their continued investment in building this sector and attracting global leaders to our city. This is how we retain talent and create pathways for young professionals in our city for the long term.”
ESD oversees New York’s Life Science Initiative, a $620 million program designed to invigorate the state’s commercial life science industry and attract, retain and grow companies in the sector. In 2025, New York was home to 3,400 life science companies and approximately 70,000 life science jobs, representing increases of 46 percent and 21 percent, respectively, from a decade ago. Nationally, New York ranks second in National Institutes of Health funding with $3.55 billion in 2025, supporting 29,000 jobs and generating $8.25 billion in economic activity, and ranks third in bioscience-related venture capital investments, number of bioscience patents, and total drug development pipeline.
Graphics: © ONE Biosciences
More Posts
Weidmüller Group Bolsters U.S. Manufacturing with $16.4m Expansion in Virginia, adding over 100 jobs
